Enlivex Ltd.
About Enlivex Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- $1.2B
- Total assets
- $2.3B
- Market cap
- $171.1M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $171.1M
- Shares outstanding
- 241.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 31, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.2B.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Enlivex Ltd..
Write a review
News about Enlivex Ltd.
News & sentiment via Polygon.io
